Patients
We are committed to developing transformative cell therapies to improve outcomes for patients with solid tumors.
Clinical Trials
We are motivated by our mission to develop curative therapies for solid tumor cancers. Testing our therapeutics for safety and efficacy in clinical trials depends on the participation of patients and their families. We are inspired by their courage in their fight against cancer and grateful for their choice to join us on this journey.
Triple-Negative Breast Cancer (TNBC)
TNBC is an aggressive cancer that metastasizes early and has few targeted therapies. The subtype accounts for an estimated 10 to 15 percent of invasive breast cancers and typically affects younger women.
LYL797 is an investigational ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness. It incorporates Lyell’s novel genetic and epigenetic reprogramming technologies, Gen-R and Epi-R.
A Phase 1 study to evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory TNBC or non-small cell lung cancer (NSCLC) is currently open for enrollment. For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.
Non-Small Cell Lung Cancer (NSCLC)
NSCLC is a common lung cancer affecting large cells of the lungs. Despite recent treatment advances, NSCLC continues to have a low five-year survival rate.
LYL797 is an investigational ROR1-targeted CAR T-cell therapy designed to overcome T-cell exhaustion and promote durable stemness. It incorporates Lyell’s novel genetic and epigenetic reprogramming technologies, Gen-R and Epi-R.
A Phase 1 study to evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory TNBC or non-small cell lung cancer (NSCLC) is currently open for enrollment. For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.
LYL845 is an autologous tumor infiltrating lymphocyte (TIL) product candidate enhanced with Epi-R reprogramming technology. In preclinical studies, Epi-R creates populations of T cells that demonstrate properties of durable stemness and anti-tumor functionality. Durable stemness is the quality that enables T cells to self-renew, proliferate, persist and generate differentiated effector cell progeny.
A Phase 1 study to evaluate the safety and tolerability of LYL845, an autologous tumor infiltrating lymphocytes (TIL) therapy will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into non-small cell lung cancer and colorectal cancer. For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.
Melanoma
Melanoma accounts for ~1% of all skin cancers but is responsible for ~80% of skin cancer-related deaths.
LYL845 is an autologous tumor infiltrating lymphocyte (TIL) product candidate enhanced with Epi-R reprogramming technology. In preclinical studies, Epi-R creates populations of T cells that demonstrate properties of durable stemness and anti-tumor functionality. Durable stemness is the quality that enables T cells to self-renew, proliferate, persist and generate differentiated effector cell progeny.
A Phase 1 study to evaluate the safety and tolerability of LYL845, an autologous tumor infiltrating lymphocytes (TIL) therapy will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into non-small cell lung cancer and colorectal cancer. For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.
Colorectal Cancer (CRC)
Colorectal cancer is the second most common cause of cancer deaths in the United States. Approximately 25% of patients have metastatic disease at diagnosis, and ~50% of patients with colorectal cancer will eventually develop metastases.
LYL845 is an autologous tumor infiltrating lymphocyte (TIL) product candidate enhanced with Epi-R reprogramming technology. In preclinical studies, Epi-R creates populations of T cells that demonstrate properties of durable stemness and anti-tumor functionality. Durable stemness is the quality that enables T cells to self-renew, proliferate, persist and generate differentiated effector cell progeny.
A Phase 1 study to evaluate the safety and tolerability of LYL845, an autologous tumor infiltrating lymphocytes (TIL) therapy will initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into non-small cell lung cancer and colorectal cancer. For more information on this clinical trial, visit ClinicalTrials.gov or email clinicaltrials@lyell.com.